Rituraj Upadhyay

Dr. Rituraj Upadhyay

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
RURituraj Upadhyay
Rituraj Upadhyay
BVBhanu Prasad Venkatesulu
Bhanu Prasad Venkatesulu
PGPrashanth Giridhar
Prashanth Giridhar
BKB.K. Kim
B.K. Kim
ASAmrish Sharma
Amrish Sharma
MHMatthew Harkenrider
Matthew Harkenrider

23 February 2025 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
RURituraj Upadhyay
Rituraj Upadhyay
AEAhmed Nader Mohammed Elguindy
Ahmed Nader Mohammed Elguindy
LSLaura Salts
Laura Salts
KDKari Donovan
Kari Donovan
SSSoma Sengupta
Soma Sengupta
Joshua PalmerJoshua Palmer
Joshua Palmer
Radiation necrosis(RN) is a dose-limiting toxicity of stereotactic radiosurgery(SRS) for brain metastases. Oral corticosteroids are not optimal for long-term management given multiple side effects. Boswellia serrata(BS) is an over-the-counter supplement traditionally known for anti-inflammatory properties and recently shown to reduce cerebral edema. We evaluated the response rates with BS in a series of patients with RN after SRS for brain metastases. We identified patients who developed any grade RN after SRS and received BS for ≥2 months, at a target dose of 4050-4500 mg daily. Primary endpoint was objective response rate(ORR), including complete response(CR) or partial response(PR), defined as ≥30% decrease in edema volume on T2-FLAIR MRI from baseline. 100 patients received BS of which 94 patients with adequate follow-up were included. Median SRS dose was 24 Gy in 3 fractions, and 44%, 47% and 9% patients had grade 1, 2, and 3 RN, respectively. The best response was CR in 12% and PR in 48%, while 28% had stable edema(SE) and 12% had progression of edema. The overall ORR was 59.6% (95% CI: 48.9 - 69.6%). ORR was 62%, 63%, and 33%, respectively for grade 1, 2, and 3, RN. The median duration of response in patients with CR or PR was 13.9 months (IQR 9 - 23). Among 69 patients (73%) who never received steroids, received prior steroids only, or had a stable or decreasing steroid requirement of ≤4 mg per day of Dexamethasone for at least >1 week prior to starting Boswellia, the ORR was 63.8%. 14% patients had CTCAE grade 1, and 2% had grade 2 gastrointestinal toxicity. 67% patients remained on BS at last follow-up. Our study suggests BS is a safe and feasible treatment option for grade 1-3 RN after SRS. Further prospective studies comparing BS with placebo are warranted.

14 February 2022 in Neuro-Oncology
Verified
Journal Article
Closed access
RURituraj Upadhyay
Rituraj Upadhyay
KLKaiping Liao
Kaiping Liao
DGDavid R Grosshans
David R Grosshans
SMSusan L McGovern
Susan L McGovern
MMMary Frances McAleer
Mary Frances McAleer
APArnold C. Paulino
Arnold C. Paulino
Background: Brainstem toxicity after radiation therapy (RT) is a devastating complication and a particular concern with proton radiation (PBT). We investigated the incidence and clinical correlates of brainstem injury in pediatric brain tumors treated with PBT. Methods: All patients 30 Gy and/or Dmax >50.4 Gy were included. Symptomatic brainstem injury (SBI) was defined as any new or progressive cranial neuropathy, ataxia, and/or motor weakness with corresponding radiographic abnormality within brainstem. Results: A total of 595 patients were reviewed and 468 (medulloblastoma = 200, gliomas = 114, ependymoma = 87, ATRT = 43) met our inclusion criteria. Median age at RT was 6.3 years and median prescribed RT dose was 54Gy [RBE]. Fifteen patients (3.2%) developed SBI, at a median of 4 months after RT. Grades 2, 3, 4, and 5 brainstem injuries were seen in 7, 5, 1, and 2 patients respectively. Asymptomatic radiographic changes were seen in 51 patients (10.9%). SBI was significantly higher in patients with age ≤3 years, female gender, ATRT histology, patients receiving high-dose chemotherapy with stem cell rescue, and those not receiving craniospinal irradiation. Patients with SBI had a significantly higher V50–52. In 2014, our institution started using strict brainstem dose constraints (Dmax ≤57 Gy, Dmean ≤52.4 Gy, and V54≤10%). There was a trend towards decrease in SBI from 4.4% (2007-2013) to 1.5% (2014–2019) (P = .089) without affecting survival. Conclusion: Our results suggest a low risk of SBI after PBT for pediatric brain tumors, comparable to photon therapy. A lower risk was seen after adopting strict brainstem dose constraints.

1 August 2023 in Stroke
Verified
Journal Article
Closed access
GMGeorgios Mantziaris
Georgios Mantziaris
SPStylianos Pikis
Stylianos Pikis
CDChloe Dumot
Chloe Dumot
SDSamantha Dayawansa
Samantha Dayawansa
RLRoman Liščák
Roman Liščák
JSJason P. Sheehan
Jason P. Sheehan
BACKGROUND: Repeat stereotactic radiosurgery (SRS) for persistent cerebral arteriovenous malformation (AVM) has generally favorable patient outcomes. However, reporting studies are limited by small patient numbers and single-institution biases. The purpose of this study was to provide the combined experience of multiple centers, in an effort to fully define the role of repeat SRS for patients with arteriovenous malformation. METHODS: This multicenter, retrospective cohort study included patients treated with repeat, single-fraction SRS between 1987 and 2022. Follow-up began at repeat SRS. The primary outcome was a favorable patient outcome, defined as a composite of nidus obliteration in the absence of hemorrhage or radiation-induced neurological deterioration. Secondary outcomes were obliteration, hemorrhage risk, and symptomatic radiation-induced changes. Competing risk analysis was performed to compute yearly rates and identify predictors for each outcome. RESULTS: The cohort comprised 505 patients (254 [50.3%] males; median [interquartile range] age, 34 [15] years) from 14 centers. The median clinical and magnetic resonance imaging follow-up was 52 (interquartile range, 61) and 47 (interquartile range, 52) months, respectively. At last follow-up, favorable outcome was achieved by 268 (53.1%) patients (5-year probability, 50% [95% CI, 45%–55%]) and obliteration by 300 (59.4%) patients (5-year probability, 56% [95% CI, 51%–61%]). Twenty-eight patients (5.6%) experienced post-SRS hemorrhage with an annual incidence rate of 1.38 per 100 patient-years. Symptomatic radiation-induced changes were evident in 28 (5.6%) patients, with most occurring in the first 3 years. Larger nidus volumes (between 2 and 4 cm 3 , subdistribution hazard, 0.61 [95% CI, 0.44–0.86]; P =0.005; >4 cm 3 , subdistribution hazard, 0.47 [95% CI, 0.32–0.7]; P <0.001) and brainstem/basal ganglia involvement (subdistribution hazard, 0.6 [95% CI, 0.45–0.81]; P <0.001) were associated with reduced probability of favorable outcome. CONCLUSIONS: Repeat SRS confers reasonable obliteration rates with a low complication risk. With most complications occurring in the first 3 years, extending the latency period to 5 years generally increases the rate of favorable patient outcomes and reduces the necessity of a third intervention.

5 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
RURituraj Upadhyay
Rituraj Upadhyay
EGEmile Gogineni
Emile Gogineni
GTGlenis Tocaj
Glenis Tocaj
SMSung Jun Ma
Sung Jun Ma
MBMarcelo Bonomi
Marcelo Bonomi
DBDukagjin M. Blakaj
Dukagjin M. Blakaj
Objectives: Patients with recurrent and metastatic head and neck cancer (HNC) have limited treatment options. ‘QuadShot’ (QS), a hypofractionated palliative radiotherapy regimen, can provide symptomatic relief and local control and may potentiate the effects of immune checkpoint inhibitors (ICIs). We compared outcomes of QS ± concurrent ICIs in the palliative treatment of HNC. Materials and Methods: We identified patients who received ≥three cycles of QS from 2017 to 2022 and excluded patients without post-treatment clinical evaluation or imaging. Outcomes for patients who received QS alone were compared to those treated with ICI concurrent with QS, defined as receipt of ICI within 4 weeks of QS. Results: Seventy patients were included, of whom 57% received concurrent ICI. Median age was 65.5 years (interquartile range [IQR]: 57.9–77.8), and 50% patients had received prior radiation to a median dose of 66 Gy (IQR: 60–70). Median follow-up was 8.8 months. Local control was significantly higher with concurrent ICIs (12-month: 85% vs. 63%, p = 0.038). Distant control (12-month: 56% vs. 63%, p = 0.629) and median overall survival (9.0 vs. 10.0 months, p = 0.850) were similar between the two groups. On multivariable analysis, concurrent ICI was a significant predictor of local control (HR for local failure: 0.238; 95% CI: 0.073–0.778; p = 0.018). Overall, 23% patients experienced grade 3 toxicities, which was similar between the two groups. Conclusions: The combination of QS with concurrent ICIs was well tolerated and significantly improved local control compared to QS alone. The median OS of 9.4 months compares favorably to historical controls for patients with HNC treated with QS. This approach represents a promising treatment option for patients with HNC unsuited for curative-intent treatment and warrants prospective evaluation.

Verified
Journal Article
Open access
PDF file
ADAastha Dhakal
Aastha Dhakal
RURituraj Upadhyay
Rituraj Upadhyay
CWCaroline Wheeler
Caroline Wheeler
RHRebecca Hoyd
Rebecca Hoyd
VKVidhya Karivedu
Vidhya Karivedu
DSDan Spakowicz
Dan Spakowicz
Purpose/Objective(s): Microbiome has been shown to affect tumorigenesis by promoting inflammation. However, the association between the upper aerodigestive microbiome and head and neck squamous cell carcinoma (HNSCC) is not well established. Hypoxia is a modifiable factor associated with poor radiation response. Our study analyzed the HNSCC tumor samples from The Cancer Genome Atlas (TCGA) to investigate the relationship between different HNSCC tumor subsites, hypoxia, and local tumor microbiome composition. Results: A total of 357 patients were included [Oral cavity (OC) = 226, Oropharynx (OPx) = 53, and Larynx/Hypopharynx (LHPx) = 78], of which 12.8%, 71.7%, and 10.3%, respectively, were HPV positive. The mean (SD) hypoxia scores were 30.18 (11.10), 24.31 (14.13), and 29.53 (12.61) in OC, OPx, and LHPx tumors, respectively, with higher values indicating greater hypoxia. The hypoxia score was significantly higher for OC tumors compared to OPx (p = 0.044) and LHPx (p = 0.002). There was no significant correlation between hypoxia and HPV status. Pseudomonas sp. in OC, Actinomyces sp. and Sulfurimonas sp. in OPx, and Filifactor, Pseudomonas and Actinomyces sp. in LHPx had the strongest association with the hypoxia score. Materials/Methods: Tumor RNAseq samples from TCGA were processed, and the R package “tmesig” was used to calculate gene expression signature, including the Buffa hypoxia (BH) score, a validated hypoxia signature using 52 hypoxia-regulated genes. Microbe relative abundances were modeled with primary tumor location and a high vs. low tertile BH score applying a gamma-distributed generalized linear regression using the “stats” package in R, with adjusted p-value < 0.05 considered significant. Conclusions: In our study, oral cavity tumors were found to be more hypoxic compared to other head and neck subsites, which could potentially contribute to their radiation resistance. For each subsite, distinct microbial populations were over-represented in hypoxic tumors in a subsite-specific manner. Further studies focusing on an association between microbiome, hypoxia, and patient outcomes are warranted.